Bottom line
A An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. Quelle der Definition: Scope and selection methodology · Glossar growth-hormone-axis combination pairing sermorelin, a GHRH(1-29) analog with historical FDA-approved finished-drug products, and ipamorelin, an A clinical-stage candidate with scientific or public relevance. Investigation is not approval, and a studied exposure is not a recommendation. Quelle der Definition: Scope and selection methodology · Glossar growth-hormone secretagogue. Each component has separate evidence, but no published randomized trial was identified for the specific combination. Evidence for either component alone cannot establish the combination's efficacy, safety, dose ratio, or stability.
No established or recommended human dose.
Name and formulation variability
| Market observation | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Market listing 1 (accessed 2026) | Sermorelin, ipamorelin | Seller-specific | Identity, purity, and sterility were not independently verified |
| Market listing 2 (accessed 2026) | Sermorelin, ipamorelin | Seller-specific | Seller testing page; not evidence of clinical equivalence or combination efficacy |
Also known as: Sermorelin/Ipamorelin and GHRH(1-29) + Ipamorelin. Informal labels such as "clean GH stack" are marketing language, not a validated clinical characterization.
Sermorelin has historical Geref records and a separate pediatric study. Ipamorelin has preclinical selectivity findings, human pharmacology, and a negative phase 2 efficacy study. Both histories stop before the marketed pair; no combination randomized trial or co-formulation study was identified.
Market source note
Market listing 1 is the RCDbio source recorded on this page; market listing 2 is Peptigrity. They are retained only to establish that the pairing is marketed, not to support identity, quality, efficacy, safety, or compatibility.
Component evidence
| Component | Development history | Combination evidence | Compatibility |
|---|---|---|---|
| Sermorelin | Historical Geref diagnostic and pediatric-treatment records; a separate A study in which participants and investigators know what is administered. Quelle der Definition: Neutral gloss; usage context: Evidence grading methodology · Glossar pediatric study. The former authorizations were product-specific and later withdrawn. | No published randomized study of the specific combination identified | No published co-formulation stability study identified |
| Ipamorelin | Evidence from in vitro or animal studies with no adequate human efficacy evidence — the atlas Grade D lane. Quelle der Definition: Evidence grading methodology · Glossar selectivity work; separate healthy-volunteer PK/PD; a negative randomized phase-2 postoperative-ileus efficacy study. | No published randomized study with sermorelin identified | No published co-formulation stability study identified |
Raun et al. reported that ipamorelin did not increase ACTH or cortisol beyond the GHRH response in conscious swine, unlike GHRP-2 and GHRP-6 in that animal model. That preclinical comparison does not establish an off-target advantage in humans or validate the sermorelin-ipamorelin combination. Gobburu et al. characterized ipamorelin PK/GH response in healthy men, while Beck et al. found no significant benefit on the primary or secondary efficacy endpoints in postoperative ileus.
Study detail
The sermorelin study was an open-label pediatric report. Ipamorelin's record includes preclinical selectivity work, small healthy-volunteer pharmacology cohorts, and a randomized postoperative-ileus study that found no significant benefit on its primary or secondary efficacy endpoints. None tested the marketed pair.
Combination-specific studies
No published human A study in which participants are assigned to the study material or a comparator by chance. Quelle der Definition: Neutral gloss; usage context: Evidence grading methodology · Glossar was identified that tests sermorelin + ipamorelin as a specific combination.
Safety and interaction uncertainties
Historical pharmaceutical-grade sermorelin data cannot establish the safety or quality of current An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. Quelle der Definition: Scope and selection methodology · Glossar material
Ipamorelin's selectivity claim comes primarily from animal pharmacology and should not be generalized to combination safety in humans
No combination-specific safety data
No published compatibility, sterility, or co-formulation stability data were identified
Regulatory and product-quality notes
Geref diagnostic (NDA 19-863) was approved December 28, 1990; the pediatric treatment presentation (NDA 20-443) was approved September 26, 1997
The sponsor reported discontinuation in 2008, and FDA withdrew both NDA approvals effective June 18, 2009. FDA later determined that the products were not withdrawn for reasons of safety or effectiveness
Neither component is currently FDA-approved for any indication
The 2026 The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. Quelle der Definition: WADA and sport regulation brief · Glossar List explicitly names sermorelin among GHRH analogues and ipamorelin among growth-hormone secretagogues and their mimetics in section S2.2.4; both are prohibited at all times
Research-grade material is not pharmaceutical GMP
Evidence gaps
No combination study (human or animal)
No dose-ratio optimisation
No co-stability data
Research-grade Sermorelin purity/consistency not equivalent to former pharmaceutical product
The seller names behind market listing 1 and 2 are retained in Sources 8 and 9 solely to document market use of the pairing. See United States regulation, WADA and sport, and the related CJC-1295 + Ipamorelin analysis.
Sources
FDA. Determination that Geref products were not withdrawn for reasons of safety or effectiveness. 78 FR 14095 (March 4, 2013). Includes the 1990 and 1997 approvals, 2008 sponsor notices, and June 18, 2009 effective withdrawal. https://www.govinfo.gov/content/pkg/FR-2013-03-04/pdf/2013-04827.pdf
FDA Orphan Drug Designations and Approvals. Sermorelin acetate (Geref), pediatric treatment marketing approval September 26, 1997. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687&sid=g1_mnxuuiosj4sj6y
Thorner M, et al.; Geref International Study Group. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PMID: 8772599. https://pubmed.ncbi.nlm.nih.gov/8772599/
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
PubChem. Sermorelin (CID 16132413). https://pubchem.ncbi.nlm.nih.gov/compound/16132413
RCDbio. Sermorelin + Ipamorelin Blend. Vendor page used only to document a marketed blend name; claims were not independently verified. https://rcdbio.co/product/sermorelin-ipamorelin-blend-peptide/
Peptigrity. Sermorelin + Ipamorelin testing. Vendor page used only to document formulation variability; claims were not independently verified. https://peptigrity.com/peptides/sermorelin-ipamorelin
World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf